17 results on '"Peter Alison"'
Search Results
2. The Indonesian Internet Addiction Questionnaires
3. 877 Intermittent dosing of the ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib promotes antitumor immunity by remodelling the tumor immune microenvironment in pre-clinical models
4. Supplementary Data from AZD4625 is a Potent and Selective Inhibitor of KRASG12C
5. Data from AZD4625 is a Potent and Selective Inhibitor of KRASG12C
6. Data from AZD4625 is a Potent and Selective Inhibitor of KRASG12C
7. Supplementary Figure from AZD4625 is a Potent and Selective Inhibitor of KRASG12C
8. Supplementary Data from AZD4625 is a Potent and Selective Inhibitor of KRASG12C
9. Supplementary Figure from AZD4625 is a Potent and Selective Inhibitor of KRASG12C
10. AZD4625 is a Potent and Selective Inhibitor of KRASG12C
11. A preclinical model of peripheral T‐cell lymphoma GATA3 reveals DNA damage response pathway vulnerability
12. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer
13. Abstract PO-20: Molecular characterization of a mouse model of peripheral T-cell lymphoma with Tfh and Th2 features
14. Abstract 2713: Discovery and characterization of AZD8701, a high affinity antisense oligonucleotide targeting FOXP3 to relieve immunosuppression in cancer
15. Abstract 2713: Discovery and characterization of AZD8701, a high affinity antisense oligonucleotide targeting FOXP3 to relieve immunosuppression in cancer
16. Abstract 5561: High-affinity antisense oligonucleotides targeting Foxp3 inhibit immunosuppressive function of regulatory T-cells and produce antitumor effects in syngeneic tumor models
17. Abstract LB-B20: High-affinity antisense oligonucleotides targeting Foxp3 inhibit immunosuppressive function of regulatory T cells and produce anti-tumor effects in syngeneic tumor models
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.